Abstract:At the Washington "2nd International Workshop on Genotoxicity Testing" (25-26 March 1999) current methodologies and data for the in vitro micronucleus test were reviewed. As a result, guidelines for the conduct of specific aspects of the protocol were developed. Agreement was achieved on the following topics: choice of cells, slide preparation, analysis of micronuclei, toxicity, use of cytochalasin-B, number of doses, and treatment/harvest times [Environ. Mol. Mutagen. 35 (2000) 167]. Because there were a number of important in vitro micronucleus validation studies in progress, it was not possible to design a definitive, internationally harmonized protocol at that time. These studies have now been completed and the data were reviewed at the Plymouth "3rd International Workshop on Genotoxicity Testing" (28-29 June 2002). Data from studies coordinated by the French Society of Genetic Toxicology, Japanese collaborative studies, European pharmaceutical industry validation studies, along with data from Lilly Research Laboratories were used to prepare conclusions on the main aspects of the in vitro micronucleus protocol. In this paper, the consensus agreements on the protocol for performing the in vitro micronucleus assay are presented. The major recommendations concern: 1. Demonstration of cell proliferation: both cell lines and lymphocytes can be used, but demonstration of cell proliferation in both control and treated cells is compulsory for the acceptance of the test. 2. Assessment of toxicity and dose range finding: assessment of toxicity should be performed by determining cell proliferation, e.g. increased cell counts (CC) or population doubling (PD) without cytochalasin-B, or e.g. cytokinesis-block proliferation index with cytochalasin-B; and by determining other markers for cytotoxicity (confluency, apoptosis, necrosis) which can provide valuable additional information. 3. Treatment schedules for cell lines and lymphocytes. 4. Choice of positive controls: without S9-mix both a clastogen (e.g. mitomycin C or bleomycin) and an aneugen (e.g. colchicine) should be included as positive controls and a clastogen that requires S9 for activity when S9-mix is used (e.g. dimethylnitrosamine, or cyclophosphamide in those cell types that cannot activate this agent directly). 5. Duplicate cultures and number of cells to be scored. 6. Repeat experiments: in lymphocytes, for each experiment blood from 2 different healthy young and non-smoking donors should be compared. In cell lines, the experiments need only to be repeated if the first one is negative. 7. Statistics: statistical significance should not be the sole factor for determining positive results. Biological meaning should serve as a guideline. Examples of statistical analyses are given.

Transferability and reproducibility of the EpiSkin™ Micronucleus Assay

Differentiated Fibroblastic Progenies of Human Embryonic Stem Cells for Toxicology Screening

3D Cell-Based Biosensor for Cell Viability and Drug Assessment by 3D Electric Cell/matrigel-Substrate Impedance Sensing.

Inter-laboratory Validation of the In-Vivo Flow Cytometric Micronucleus Analysis Method (microflow®) in China

A ready-to-use integrated in vitro skin corrosion and irritation testing strategy using EpiSkin™ model in China

Validation of the 3D reconstructed human skin Comet assay, an animal-free alternative for following-up positive results from standard in vitro genotoxicity assays

Validation study of a new reconstructed human epidermis model EPiTRI for in vitro skin irritation test according to OECD guidelines

Skin Toxicity Assessment of Silver Nanoparticles in a 3D Epidermal Model Compared to 2D Keratinocytes

An epidermal equivalent assay for identification and ranking potency of contact sensitizers

A multi-biomarker micronucleus assay using imaging flow cytometry

Inter-laboratory automation of the in vitro micronucleus assay using imaging flow cytometry and deep learning

Testing Method Development and Validation for in Vitro Skin Irritation Testing (SIT) by Using Reconstructed Human Epidermis (RhE) Skin Equivalent - EPiTRI®

Report from the in vitro micronucleus assay working group

An Automated, Single Cell Quantitative Imaging Microscopy Approach to Assess Micronucleus Formation, Genotoxicity and Chromosome Instability

Epidermis-on-a-chip System to Develop Skin Barrier and Melanin Mimicking Model

In Vitro Dendritic Cell-Based Test for Skin Sensitizers Identification and Potency Estimation

Intra-laboratory Study to Determine the Reproducibility of LLNA:BrdU-ELISA for the Prediction of the Skin Sensitizing Potential of Chemicals.

How to facilitate the implementation of 3D models in China by applying good in vitro method practice for regulatory use

Development of a novel flow cytometry‐based approach for reticulocytes micronucleus test in rat peripheral blood